Skip to content

Author

E. O'Reilly

6 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Molecular landscape of anaplastic transformation in pancreatic ductal adenocarcinoma.

Pancreatic ductal adenocarcinoma (PDAC) with anaplastic features is a rare and highly aggressive subtype with an extremely poor prognosis. However, the molecular mechanisms underlying anaplastic transformation remain poorly understood. To characterize the anaplastic transformation molecular landscape, we analyzed genom...

Akimasa Hayashi, Shota Sasagawa, Takahiro Shibayama et al. · 0 citations
Open access Sep 2026

Systemic iron sequestration restricts the intratumoral CD8+ T cell landscape in pancreas cancer

Systemic iron sequestration occurs frequently in cancer due to inflammation-driven expression of the iron-regulatory hormone hepcidin. The impact of systemic iron availability on tumoral immunity is unclear. Here, we show that elevated serum hepcidin is associated with reduced survival and decreased intratumoral CD8+ T...

J. Schoenfeld, Jahi J. Noel, Christopher S. McGinnis et al. · 0 citations
Review Sep 2026

Abstract A042: ctDNA KRAS detection in pancreatic ductal adenocarcinoma: Platform concordance, sensitivity and clinical associations in a contemporary cohort

Multiple circulating tumor DNA (ctDNA) platforms are available for KRAS mutation detection in pancreatic ductal adenocarcinoma (PDAC), including broad next-generation sequencing (NGS) and targeted quantitative polymerase chain reaction (qPCR) assays, yet comparisons of performance and concordance are limited. We...

Jennifer Guo, Michael S. May, Michael F. Berger et al. · 0 citations
Sep 2026

Abstract A140: Patient-derived organoids and precision medicine: Insights from the PASS-01 clinical trial in PDAC

Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed at an advanced stage with limited treatment options. Patient-derived organoids (PDOs) can model tumors, identify determinants of therapeutic response, and support precision medicine. In the multi-institutional PASS-01 trial of metastatic PDAC, biopsies f...

A. Habowski, Fatim M. Kouassi, James A. Rouse et al. · 0 citations
Open access Sep 2026

Neoantigen-reactive CD8+ T cell engagement marks exceptional survivors of pancreatic cancer

Pancreatic cancer (PC) is largely refractory to immune checkpoint blockade (ICB), although homologous recombination-deficient (HRD) tumors may derive benefit. In the POLAR trial of maintenance pembrolizumab plus olaparib after platinum-based chemotherapy for metastatic PC, responses remained heterogeneous. To define de...

M. Hilmi, J. Schoenfeld, Wilson H. McKerrow et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.